Therapeutic role of JAK inhibitors in hepatogastrointestinal diseases

i

This article has been updated. A Correction to this article was published on .

i

The Original Article was published on

i

The Original Article was published on

i

This article has been updated

i

This article was retracted on

i

This article has been updated

Abstract

Janus kinase (JAK) inhibitors represent a major advancement in the management of immune-mediated inflammatory diseases. A balanced approach that carefully weighs therapeutic benefits against potential risks is essential. Through appropriate patient selection, close monitoring, and open physician–patient communication, the clinical potential of JAK inhibitors can be optimized while minimizing adverse outcomes. Nine JAK inhibitors have demonstrated utility in hepatogastrointestinal disorders; however, only two have FDA approval. JAK inhibitors are classified into reversible (competitive) and irreversible (covalent) inhibitors according to their chemical binding with amino acids. This review discusses the safety profile, adverse effects, and molecular selectivity of JAK inhibitors, and highlights their therapeutic roles in hepatogastrointestinal diseases, including inflammatory bowel disease, hepatic fibrosis, hepatocellular carcinoma, autoimmune diseases associated with cancer therapy in post-transplant patients, eosinophilic esophagitis, metabolic syndrome, and metabolic dysfunction-associated steatotic liver disease, and acute graft-versus-host disease following liver transplantation.

Keywords

JAK inhibitors / JAK/STAT pathway / IBD / eosinophilic esophagitis / metabolic syndrome / MASLD / IBD following liver transplantation / acute graft versus host rejection after liver transplantation

CHANGE HISTORY

A Correction to this paper has been published:
https://doi.org

The Retraction Note was updated to reflect reception of statements of disagreement from all authors.

This article has been retracted.Please see the Retraction Notice for more detail:
https://doi.org

References

[1] Yamaoka K, Saharinen P, Pesu M, Holt VE 3rd, Silvennoinen O, O’Shea JJ. The Janus kinases (Jaks). Genome Biol. 2004; 5: 253.

[2] Wilks AF. Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction. Proc Natl Acad Sci U S A. 1989; 86: 1603-7.

[3] Kotyla PJ. Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients? Biomed Res Int. 2018; 2018: 7492904.

[4] Xu P, Shen P, Yu B, Xu X, Ge R, Cheng X, et al. Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders. Eur J Med Chem. 2020; 192: 112155.

[5] Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017; 16: 843-62.

[6] Yasuda T, Fukada T, Nishida K, Nakayama M, Matsuda M, Miura I, et al. Hyperactivation of JAK1 tyrosine kinase induces stepwise, progressive pruritic dermatitis. J Clin Invest. 2016; 126: 2064-76.

[7] Harris C, Cummings JRF. JAK1 inhibition and inflammatory bowel disease. Rheumatology (Oxford). 2021; 60: ii45-51.

[8] Buchert M, Burns CJ, Ernst M. Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene. 2016; 35: 939-51.

[9] Liau NPD, Laktyushin A, Morris R, Sandow JJ, Nicola NA, Kershaw NJ, et al. Enzymatic Characterization of Wild-Type and Mutant Janus Kinase 1. Cancers (Basel). 2019; 11: 1701.

[10] Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford). 2019; 58: 953-62.

[11] Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009; 228: 273-87.

[12] Ferrao R, Lupardus PJ. The Janus Kinase (JAK) FERM and SH2 Domains: Bringing Specificity to JAK-Receptor Interactions. Front Endocrinol (Lausanne). 2017; 8: 71.

[13] Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis. 2021; 80: 865-75.

[14] Morand E, Merola JF, Tanaka Y, Gladman D, Fleischmann R. TYK2: an emerging therapeutic target in rheumatic disease. Nat Rev Rheumatol. 2024; 20: 232-40.

[15] Hu X, Chen J, Wang L, Ivashkiv LB. Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation. J Leukoc Biol. 2007; 82: 237-43.

[16] Lin CM, Cooles FA, Isaacs JD. Basic Mechanisms of JAK Inhibition. Mediterr J Rheumatol. 2020; 31: 100-4.

[17] Agrawal M, Kim ES, Colombel JF. JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications. J Crohns Colitis. 2020; 14: S755-60.

[18] Herrera-deGuise C, Serra-Ruiz X, Lastiri E, Borruel N. JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases. Front Med (Lausanne). 2023; 10: 1089099.

[19] Gadina M, Johnson C, Schwartz D, Bonelli M, Hasni S, Kanno Y, et al. Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. J Leukoc Biol. 2018; 104: 499-514.

[20] Latham BD, Geffert RM, Jackson KD. Kinase Inhibitors FDA Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities. Drug Metab Dispos. 2024; 52: 479-92.

[21] Zurba Y, Gros B, Shehab M. Exploring the Pipeline of Novel Therapies for Inflammatory Bowel Disease; State of the Art Review. Biomedicines. 2023; 11: 747.

[22] Leroy E, Constantinescu SN. Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition. Leukemia. 2017; 31: 1023-38.

[23] Vainchenker W, Leroy E, Gilles L, Marty C, Plo I, Constantinescu SN. JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. F1000Res. 2018; 7: 82.

[24] Blair HA. Ritlecitinib: First Approval. Drugs. 2023; 83: 1315-21.

[25] Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2023; 82: 119-29.

[26] Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al.; ORAL Surveillance Investigators. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022; 386: 316-26.

[27] Charles-Schoeman C, Fleischmann R, Mysler E, Greenwald M, Ytterberg SR, Koch GG, et al. Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk-Enriched Rheumatoid Arthritis Patients. Arthritis Rheumatol. 2024; 76: 1218-29.

[28] Charles-Schoeman C, Choy E, McInnes IB, Mysler E, Nash P, Yamaoka K, et al. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. RMD Open. 2023; 9: e003392.

[29] Lowell JA, Sharma G, Swaminath A, Sultan K. Pharmacologic Anticoagulation Is Associated With a Lower Risk of Recurrent Venous Thromboembolic Events During Janus Kinase Inhibitor Use for Patients With a Prior Thrombosis. Inflamm Bowel Dis. 2025; 31: 725-32.

[30] Guillo L, Amiot A, Serrero M, Altwegg R, Roblin X, Atanasiu C, et al.; FOCUS Study Group. Prevalence of Self-Reported Venous Thromboembolism and Cardiovascular Risk Factors in Patients with Ulcerative Colitis: The GETAID FOCUS Study. Dig Dis Sci. 2022; 67: 4525-32.

[31] Bernstein CN, Nugent Z, Singh H. Persistently High Rate of Venous Thromboembolic Disease in Inflammatory Bowel Disease: A Population-Based Study. Am J Gastroenterol. 2021; 116: 1476-84.

[32] Alsakarneh S, Madi M, Jaber F, Farraye FA, Faye AS, Caldera FD. Major Adverse Cardiovascular Events in Patients With IBD Taking Anti-TNF vs JAK Inhibitors: A Propensity Matched Cohort Analysis. Am J Gastroenterol. 2024; 119: pS733.

[33] Yang H, An T, Zhao Y, Shi X, Wang B, Zhang Q. Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis. Ann Med. 2025; 57: 2455536.

[34] Olivera PA, Dignass A, Dubinsky MC, Peretto G, Kotze PG, Dotan I, et al. Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus. Dig Liver Dis. 2024; 56: 1270-80.

[35] Sands BE, Taub PR, Armuzzi A, Friedman GS, Moscariello M, Lawendy N, et al. Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020; 18: 123-32.e3.

[36] Anderson K, Nelson CH, Gong Q, Alani M, Tarnowski T, Othman AA. Assessment of the Effect of Filgotinib on the Pharmacokinetics of Atorvastatin, Pravastatin, and Rosuvastatin in Healthy Adult Participants. Clin Pharmacol Drug Dev. 2022; 11: 235-45.

[37] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS [Internet]. [cited 2026 Mar 15]. Available from: https://www.ema.europa.eu/en/documents/product-information/olumiant-epar-product-information_en.pdf

[38] Deepak P, Alayo QA, Khatiwada A, Lin B, Fenster M, Dimopoulos C, et al. Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2021; 19: 1592-601.e3.

[39] Panaccione R, Panés J, Peyrin-Biroulet L, Colombel JF, Lindsay JO, Baert F, et al. Long-Term Safety of Upadacitinib in Patients With Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 Studies. Clin Gastroenterol Hepatol. 2026:S1542-356500145-X.

[40] Zhang Z, Deng W, Wu Q, Sun L. Tuberculosis, hepatitis B and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis. Immunotherapy. 2019; 11: 321-33.

[41] Winthrop K, Isaacs J, Calabrese L, Mittal D, Desai S, Barry J, et al. Opportunistic infections associated with Janus kinase inhibitor treatment for rheumatoid arthritis: A structured literature review. Semin Arthritis Rheum. 2023; 58: 152120.

[42] Sandborn WJ, Panés J, D’Haens GR, Sands BE, Su C, Moscariello M, et al. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. Clin Gastroenterol Hepatol. 2019; 17: 1541-50.

[43] Panés J, Loftus EV, Higgins PDR, Lindsay JO, Zhou W, Yao X, et al. Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results. Inflamm Bowel Dis. 2023; 29: 1421-30.

[44] Winthrop KL, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014; 66: 2675-84.

[45] Loganantharaj N, Mishra K, Charabaty A. How To Safely Use JAK Inhibitors in Patients with Inflammatory Bowel Disease. Curr Treat Options Gastro. 2025; 23: 19.

[46] Staying Up to Date with COVID-19 Vaccines [Internet]. [cited 2026 Apr 7]. Available from: https://www.cdc.gov/covid/vaccines/stay-up-to-date.html

[47] Almeida NC, Parameswaran L, DeHaan EN, Wyper H, Rahman F, Jiang Q, et al. Immunogenicity and Safety of the Bivalent Respiratory Syncytial Virus Prefusion F Subunit Vaccine in Immunocompromised or Renally Impaired Adults. Vaccines (Basel). 2025; 13: 328.

[48] Goldman A, Raschi E, Druyan A, Sharif K, Lahat A, Ben-Zvi I, et al. Gastrointestinal Perforations Associated With JAK Inhibitors: A Disproportionality Analysis of the FDA Adverse Event Reporting System. United European Gastroenterol J. 2025; 13: 566-75.

[49] Russell MD, Stovin C, Alveyn E, Adeyemi O, Chan CKD, Patel V, et al. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. Ann Rheum Dis. 2023; 82: 1059-67.

[50] Curtis JR, Yamaoka K, Chen YH, Bhatt DL, Gunay LM, Sugiyama N, et al. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023; 82: 331-43.

[51] Panaccione R, Collins EB, Melmed GY, Vermeire S, Danese S, Higgins PDR, et al. Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis. Crohns Colitis 360. 2023; 5: otad009.

[52] Samuel C, Cornman H, Kambala A, Kwatra SG. A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring. Dermatol Ther (Heidelb). 2023; 13: 729-49.

[53] Honap S, Temido MJ, Shakweh E, Badrulhisham F, Shields N, Mehta S, et al.; JAKne International Study Group. Janus Kinase Inhibitor-Induced Acne in Inflammatory Bowel Disease: An International, Multicenter, Retrospective Cohort Study. Clin Gastroenterol Hepatol. 2026; 24: 484-92.e7.

[54] Mahadevan U, Levy G, Gensler L, Ali M, Lacerda AP, Wegrzyn L, et al. Pregnancy Outcomes in Patients Treated with Upadacitinib: Analysis of Data from Clinical Trials and Postmarketing Reports. Drug Saf. 2024; 47: 1039-49.

[55] Sandborn WJ, Panés J, Sands BE, Reinisch W, Su C, Lawendy N, et al. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment Pharmacol Ther. 2019; 50: 1068-76.

[56] Mahadevan U, Seow CH, Barnes EL, Chaparro M, Flanagan E, Friedman S, et al.; Global Consensus Group for Pregnancy and IBD. Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2025; 23: S1-60.

[57] Antonioli L, Armuzzi A, Fantini MC, Fornai M. JAK inhibitors: an evidence-based choice of the most appropriate molecule. Front Pharmacol. 2024; 15: 1494901.

[58] Namour F, Anderson K, Nelson C, Tasset C. Filgotinib: A Clinical Pharmacology Review. Clin Pharmacokinet. 2022; 61: 819-32.

[59] Reinisch W, Hellstrom W, Dolhain RJEM, Sikka S, Westhovens R, Mehta R, et al. Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies. Ann Rheum Dis. 2023; 82: 1049-58.

[60] Winthrop KL, Cohen SB. Oral surveillance and JAK inhibitor safety: the theory of relativity. Nat Rev Rheumatol. 2022; 18: 301-4.

[61] Bertin L, Savarino EV. JAK Inhibitors: A Double-Edged Sword in Immune-Mediated Diseases Management. United European Gastroenterol J. 2025; 13: 505-7.

[62] Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017; 13: 234-43.

[63] Winthrop KL, Korman N, Abramovits W, Rottinghaus ST, Tan H, Gardner A, et al. T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment. J Am Acad Dermatol. 2018; 78: 1149-55.e1.

[64] Chen L, Zhang C, Niu R, Xiong S, He J, Wang Y, et al. Multi-Omics Biomarkers for Predicting Efficacy of Biologic and Small-Molecule Therapies in Adults With Inflammatory Bowel Disease: A Systematic Review. United European Gastroenterol J. 2025; 13: 517-30.

[65] Reinisch W, Serone A, Hébuterne X, Kühbacher T, Kłopocka M, Roblin X, et al. Mucosal p-STAT1/3 correlates with histologic disease activity in Crohn’s disease and is responsive to filgotinib. Tissue Barriers. 2023; 11: 2088961.

[66] Hassan-Zahraee M, Ye Z, Xi L, Dushin E, Lee J, Romatowski J, et al. Baseline Serum and Stool Microbiome Biomarkers Predict Clinical Efficacy and Tissue Molecular Response After Ritlecitinib Induction Therapy in Ulcerative Colitis. J Crohns Colitis. 2024; 18: 1361-70.

[67] Joustra V, Li Yim AYF, van Gennep S, Hageman I, de Waard T, Levin E, et al. Peripheral Blood DNA Methylation Signatures and Response to Tofacitinib in Moderate-to-severe Ulcerative Colitis. J Crohns Colitis. 2024; 18: 1179-89.

[68] Verstockt B, Verstockt S, Alsaoud D, Sabino J, Ferrante M, Vermeire S. P385 A mucosal marker predicting tofacitinib induced an endoscopic response in ulcerative colitis. J Crohns Colitis. 2020; 14: S358-9.

[69] Honap S, Agorogianni A, Colwill MJ, Mehta SK, Donovan F, Pollok R, et al. JAK inhibitors for inflammatory bowel disease: recent advances. Frontline Gastroenterol. 2023; 15: 59-69.

[70] Flanagan ME, Blumenkopf TA, Brissette WH, Brown MF, Casavant JM, Shang-Poa C, et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem. 2010; 53: 8468-84.

[71] Sandborn WJ, Lawendy N, Danese S, Su C, Loftus EV Jr, Hart A, et al. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. Aliment Pharmacol Ther. 2022; 55: 464-78.

[72] Vermeire S, Su C, Lawendy N, Kobayashi T, Sandborn WJ, Rubin DT, et al. Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial. J Crohns Colitis. 2021; 15: 1130-41.

[73] Filgotinib for treating moderately to severely active ulcerative colitis [Internet]. NICE; c2026 [cited 2025 Oct 13]. Available from: https://www.nice.org.uk/guidance/ta792

[74] Upadacitinib for treating moderately to severely active ulcerative colitis [Internet]. NICE; c2026 [cited 2025 Dec 9]. Available from: https://www.nice.org.uk/guidance/ta856

[75] Upadacitinib for previously treated moderately to severely active Crohn’s disease [Internet]. NICE; c2026 [cited 2025 Dec 9]. Available from: https://www.nice.org.uk/guidance/ta905

[76] Hardwick RN, Brassil P, Badagnani I, Perkins K, Obedencio GP, Kim AS, et al. Gut-Selective Design of Orally Administered Izencitinib (TD-1473) Limits Systemic Exposure and Effects of Janus Kinase Inhibition in Nonclinical Species. Toxicol Sci. 2022; 186: 323-37.

[77] Sands BE, Sandborn WJ, Feagan BG, Lichtenstein GR, Zhang H, Strauss R, et al.; Peficitinib-UC Study Group. Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study. J Crohns Colitis. 2018; 12: 1158-69.

[78] Sandborn WJ, Danese S, Leszczyszyn J, Romatowski J, Altintas E, Peeva E, et al. Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study. Clin Gastroenterol Hepatol. 2023; 21: 2616-28.e7.

[79] Xie JH, Gillooly K, Zhang Y, Yang X, Zupa-Fernandez A, Cheng L, et al. BMS-986165 is a highly potent and selective allosteric inhibitor of TYK2, Blocks Il-12, IL-23 and type I interferon signaling and provides for robust efficacy in preclinical models of inflammatory bowel disease. Gastroenterology. 2018; 154: S-1357.

[80] Chen B, Zhong J, Li X, Pan F, Ding Y, Zhang Y, et al. Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study. Gastroenterology. 2022; 163: 1555-68.

[81] Taxonera C, Olivares D, Alba C. Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis. Inflamm Bowel Dis. 2022; 28: 32-40.

[82] Akiyama S, Cohen NA, Kayal M, Dubinsky MC, Colombel JF, Rubin DT. Treatment of Chronic Inflammatory Pouch Conditions With Tofacitinib: A Case Series From 2 Tertiary IBD Centers in the United States. Inflamm Bowel Dis. 2023; 29: 1504-7.

[83] de Jong DC, Goetgebuer R, Müskens BLM, Neefjes-Borst EA, Gecse KB, Löwenberg M, et al. Tofacitinib for the treatment of chronic pouchitis: A pilot study. United European Gastroenterol J. 2025; 13: 201-9.

[84] Jyseleca 200 mg film-coated tablets [Internet]. [cited 2025 Dec 13]. Available from: https://www.medicines.org.uk/emc/product/11810/smpc

[85] Van Rompaey L, Galien R, van der Aar EM, Clement-Lacroix P, Nelles L, Smets B, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol. 2013; 191: 3568-77.

[86] Tanaka Y, Kavanaugh A, Wicklund J, McInnes IB. Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials. Mod Rheumatol. 2022; 32: 1-11.

[87] Feagan BG, Danese S, Loftus EV Jr, Vermeire S, Schreiber S, Ritter T, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021; 397: 2372-84.

[88] Efficacy and Safety Outcomes Up to ~4 Years of Treatment With Filgotinib 200 mg Among Patients With Ulcerative Colitis: Results From the SELECTIONLTE Study. Gastroenterol Hepatol (N Y). 2023; 19: 10-1.

[89] van Asselt ADI, Armstrong N, Kimman M, Peeters A, McDermott K, Stirk L, et al. Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2023; 41: 239-51.

[90] D’Amico F, Magro f, Peyrin-Biroulet L, Danese S. Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. J Crohns Colitis. 2022; 16: 835-44.

[91] Núñez P, Quera R, Yarur AJ. Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases. Drugs. 2023; 83: 299-314.

[92] Sandborn WJ, Ghosh S, Panes J, Schreiber S, D’Haens G, Tanida S, et al. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis. Gastroenterology. 2020; 158: 2139-49.e14.

[93] Sandborn WJ, Feagan BG, Loftus EV Jr, Peyrin-Biroulet L, Van Assche G, D’Haens G, et al. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease. Gastroenterology. 2020; 158: 2123-38.e8.

[94] Lefevre PLC, Vande Casteele N. Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease. J Crohns Colitis. 2020; 14: S725-36.

[95] Irani M, Fan C, Glassner K, Abraham BP. Clinical Evaluation of Upadacitinib in the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (UC): Patient Selection and Reported Outcomes. Clin Exp Gastroenterol. 2023; 16: 21-8.

[96] Vermeire S, Danese S, Zhou W, Klaff J, Ilo D, Yao X, et al. DOP41 Efficacy and safety of extended induction treatment with upadacitinib 45 mg once daily followed by maintenance upadacitinib 15 or 30 mg once daily in patients with moderately to severely active Ulcerative Colitis. J Crohns Colitis. 2022; 16: i090-1.

[97] Kaniewska M, Lewandowski K, Krogulecki M, Filipiuk A, Gonciarz M, Pietrzak A, et al. Efficacy of Upadacitinib Induction Treatment in Moderate-to-Severe Ulcerative Colitis Including Intestinal Ultrasound Assessment: A Multicenter, Real-World Observational Study. J Clin Med. 2025; 14: 1695.

[98] Colombel JF, Lacerda AP, Irving PM, Panaccione R, Reinisch W, Rieder F, et al. Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn’s Disease: A Post Hoc Analysis of 3 Phase 3 Trials. Clin Gastroenterol Hepatol. 2025; 23: 1019-29.

[99] Mohamed MF, Bhatnagar S, Parmentier JM, Nakasato P, Wung P. Upadacitinib: Mechanism of action, clinical, and translational science. Clin Transl Sci. 2024; 17: e13688.

[100] Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, et al. Safety profile of upadacitinib over 15000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023; 9: e002735.

[101] Cheng E, Zhang X, Wilson KS, Wang DH, Park JY, Huo X, et al. JAK-STAT6 Pathway Inhibitors Block Eotaxin-3 Secretion by Epithelial Cells and Fibroblasts from Esophageal Eosinophilia Patients: Promising Agents to Improve Inflammation and Prevent Fibrosis in EoE. PLoS One. 2016; 11: e0157376.

[102] Con D, Hilley P, Chin S, Corte C, Hafeez B, Testro A, et al. Safety and Effectiveness of Janus Kinase Inhibitors in the Management of Inflammatory Bowel Disease Following Liver Transplantation. J Crohns Colitis. 2024; 18: 1505-9.

[103] Timper K, Brüning JC. Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity. Dis Model Mech. 2017; 10: 679-89.

[104] Zhang X, Zhang G, Zhang H, Karin M, Bai H, Cai D. Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell. 2008; 135: 61-73.

[105] Wunderlich CM, Hövelmeyer N, Wunderlich FT. Mechanisms of chronic JAK-STAT3-SOCS3 signaling in obesity. JAKSTAT. 2013; 2: e23878.

[106] Qurania KR, Ikeda K, Wardhana DA, Barinda AJ, Nugroho DB, Kuribayashi Y, et al. Systemic inhibition of Janus kinase induces browning of white adipose tissue and ameliorates obesity-related metabolic disorders. Biochem Biophys Res Commun. 2018; 502: 123-8.

[107] Charles-Messance H, Mitchelson KAJ, De Marco Castro E, Sheedy FJ, Roche HM. Regulating metabolic inflammation by nutritional modulation. J Allergy Clin Immunol. 2020; 146: 706-20.

[108] Thirone AC, JeBailey L, Bilan PJ, Klip A. Opposite effect of JAK2 on insulin-dependent activation of mitogen-activated protein kinases and Akt in muscle cells: possible target to ameliorate insulin resistance. Diabetes. 2006; 55: 942-51.

[109] Kern L, Mittenbühler MJ, Vesting AJ, Ostermann AL, Wunderlich CM, Wunderlich FT. Obesity-Induced TNFα and IL-6 Signaling: The Missing Link between Obesity and Inflammation-Driven Liver and Colorectal Cancers. Cancers (Basel). 2018; 11: 24.

[110] Collotta D, Franchina MP, Carlucci V, Collino M. Recent advances in JAK inhibitors for the treatment of metabolic syndrome. Front Pharmacol. 2023; 14: 1245535.

[111] Li H, Meng Y, He S, Tan X, Zhang Y, Zhang X, et al. Macrophages, Chronic Inflammation, and Insulin Resistance. Cells. 2022; 11: 3001.

[112] Desai HR, Sivasubramaniyam T, Revelo XS, Schroer SA, Luk CT, Rikkala PR, et al. Macrophage JAK2 deficiency protects against high-fat diet-induced inflammation. Sci Rep. 2017; 7: 7653.

[113] Corbit KC, Camporez JPG, Tran JL, Wilson CG, Lowe DA, Nordstrom SM, et al. Adipocyte JAK2 mediates growth hormone-induced hepatic insulin resistance. JCI Insight. 2017; 2:e91001.

[114] Meunier L, Clerc C, Meszaros M. Use of Tofacitinib for Ulcerative Colitis in a Liver Transplant Patient. J Crohns Colitis. 2021; 15: 695.

[115] Wang B, Lu Y, Yu L, Liu C, Wu Z, Liu X. Diagnosis and treatment for graft-versus-host disease after liver transplantation: two case reports. Transplant Proc. 2007; 39: 1696-8.

[116] Chaib E, Silva FD, Figueira ER, Lima FR, Andraus W, D’Albuquerque LA. Graft-versus-host disease after liver transplantation. Clinics (Sao Paulo). 2011; 66: 1115-8.

[117] Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, et al.; REACH2 Trial Group. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. N Engl J Med. 2020; 382: 1800-10.

[118] Assadiasl S, Mojtahedi H, Nicknam MH. JAK Inhibitors in Solid Organ Transplantation. J Clin Pharmacol. 2023; 63: 1330-43.

[119] Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN, Chen YB, et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020; 135: 1739-49.

[120] Mendoza R, Liu L, Sam A, Abdel-Azim H, Greas M, Dao H. Acute graft versus host disease postliver transplant with mucocutaneous manifestations and pancytopenia: Remission with Janus kinase inhibitor. JAAD Case Rep. 2025; 62: 103-6.